1.2308

12.09% -0.1692

Therapeuticsmd Inc (TXMD)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Therapeuticsmd Inc stock is traded at $1.2308, with a volume of 78,276. It is down -12.09% in the last 24 hours and down -23.08% over the past month. TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Previous Close:

$1.40

Open:

$1.4

24h Volume:

78,276

Relative Volume:

5.03

Market Cap:

$16.03M

Revenue:

$996.00K

Net Income/Loss:

$-6.09M

P/E Ratio:

0.2741

EPS:

4.49

Net Cash Flow:

$-9.76M

1W Performance:

-19.03%

1M Performance:

-23.08%

6M Performance:

-44.56%

1Y Performance:

-45.78%

1-Day Range:

$1.15

$1.45

1-Week Range:

$1.15

$1.55

52-Week Range:

$1.15

$3.07

Therapeuticsmd Inc Stock (TXMD) Company Profile

Name

Therapeuticsmd Inc

Sector

Healthcare (1200)

Industry

Drug Manufacturers - Specialty & Generic (87)

Phone

561-961-1900

Address

951 YAMATO ROAD, SUITE 220, BOCA RATON, FL

Employee

Twitter

@TherapeuticsMD

Next Earnings Date

2024-11-12

Latest SEC Filings

TXMD's Discussions on Twitter

Compare TXMD with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TXMD	1.2287	16.03M	996.00K	-6.09M	-9.76M	4.49
ZTS	176.43	79.52B	9.15B	2.43B	2.31B	4.92
TAK	13.54	43.13B	30.27B	1.93B	3.45B	0.444
HLN	9.425	42.57B	14.26B	1.55B	0	0.3327
TEVA	16.46	18.56B	16.77B	-959.00M	1.37B	-2.00
VTRS	12.99	15.37B	15.24B	-646.50M	1.88B	1.53

Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Aug-07-20	Downgrade	Jefferies	Hold → Underperform
May-19-20	Downgrade	JP Morgan	Overweight → Neutral
Dec-02-19	Initiated	Guggenheim	Buy
Oct-17-19	Initiated	H.C. Wainwright	Buy
Apr-30-19	Resumed	Noble Capital Markets	Outperform
Jun-15-18	Initiated	JP Morgan	Overweight
Sep-08-17	Initiated	Morgan Stanley	Equal-Weight
Jul-11-17	Upgrade	Oppenheimer	Perform → Outperform
May-09-17	Downgrade	Oppenheimer	Outperform → Perform
Nov-22-16	Resumed	Jefferies	Buy
Nov-22-16	Initiated	Oppenheimer	Outperform
Nov-07-16	Resumed	Guggenheim	Buy
Apr-04-16	Initiated	Goldman	Buy
Dec-08-15	Reiterated	Jefferies	Buy
Dec-08-15	Reiterated	Stifel	Buy
Sep-21-15	Reiterated	Jefferies	Buy
Jun-09-15	Initiated	Guggenheim	Buy
Jul-08-14	Initiated	FBR Capital	Outperform
Apr-17-14	Reiterated	Noble Financial	Buy
Jan-28-14	Reiterated	Noble Financial	Buy

View All

Therapeuticsmd Inc Stock (TXMD) Latest News

Nov 15, 2024

TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch

Nov 15, 2024

TXMD stock touches 52-week low at $1.43 amid market challenges - Investing.com

Nov 15, 2024

TherapeuticsMD Third Quarter 2024 Earnings: US$0.049 loss per share (vs US$0.13 loss in 3Q 2023) - Yahoo Finance

Nov 15, 2024

TherapeuticsMD, Inc. (NASDAQ:TXMD) Sees Large Increase in Short Interest - Defense World

Nov 15, 2024

Nov 14, 2024

TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch

Nov 14, 2024

Nov 13, 2024

TherapeuticsMD Inc. stock outperforms competitors despite losses on the day - MarketWatch

Nov 13, 2024

Nov 12, 2024

TherapeuticsMD Reports Reduced Losses Amid Strategic Shift - TipRanks

Nov 12, 2024

TherapeuticsMD: Q3 Earnings Snapshot - Houston Chronicle

Nov 12, 2024